Compare · Research-Use-Only
AOD-9604 vs 5-Amino-1MQ
Both are studied in metabolic and adipose-tissue research, and neither is what it is often marketed as. AOD-9604 is a growth-hormone fragment whose clinical obesity program failed its Phase IIb endpoint. 5-Amino-1MQ is not a peptide at all but a small-molecule NNMT inhibitor, with a literature that remains entirely preclinical.
AOD-9604
AOD-9604 is a synthetic hexadecapeptide corresponding to the C-terminal lipolytic domain of human growth hormone, residues 177-191, with an added N-terminal tyrosine and a disulfide bond between its two cysteines. It was developed on the hypothesis that the lipolytic and anti-lipogenic activity of growth hormone is separable from its somatogenic activity, which is mediated by GH receptor dimerization and downstream JAK2/STAT5 signaling leading to hepatic IGF-1 production. Consistent with that separation, AOD-9604 does not compete for the growth hormone receptor and does not induce cell proliferation or raise IGF-1 in the systems studied, and in rodents it did not reproduce the hyperglycemia and insulin resistance seen with full-length growth hormone. In obese rodent models, chronic administration reduced body weight gain and increased whole-body fat oxidation, and was associated with increased adipose beta-3 adrenergic receptor expression. Importantly, the frequently repeated claim that AOD-9604 acts through beta-3 adrenergic receptor agonism is contradicted by the primary literature: Heffernan and colleagues tested the peptide in beta-3 adrenergic receptor knockout mice and concluded that the lipolytic actions of both growth hormone and AOD-9604 are not mediated directly through that receptor. The precise molecular target through which AOD-9604 exerts its rodent lipolytic effect has not been definitively established. In anti-doping metabolism work the parent peptide is rapidly degraded, with a shorter fragment identified as a comparatively stable metabolite.
5-Amino-1MQ
5-Amino-1MQ is a cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic methyltransferase that transfers a methyl group from S-adenosylmethionine to nicotinamide, yielding 1-methylnicotinamide and S-adenosylhomocysteine. It is not a peptide. Because nicotinamide is the substrate for the NAD+ salvage pathway via NAMPT, high methyltransferase flux diverts nicotinamide away from NAD+ regeneration while simultaneously consuming S-adenosylmethionine, placing the enzyme at the intersection of cellular NAD+ availability and methylation potential. Expression of the enzyme is markedly elevated in white adipose tissue and liver in obesity, which provided the rationale for pharmacological inhibition. 5-Amino-1MQ is a quinolinium — a permanently charged cation — and membrane permeability was the principal medicinal-chemistry obstacle for this compound class; the reported advance of the methylquinolinium series was achieving intracellular access despite that charge. Neelakantan and colleagues characterized the compound as an analog from their initial inhibitor series with a half-maximal inhibitory concentration of approximately 1 micromolar against the enzyme. Downstream consequences reported in treated adipocytes and mouse tissue are consistent with restored nicotinamide and NAD+ pools and increased methylation-dependent flux, with associated changes in sirtuin-dependent signaling and polyamine metabolism. A substantial fraction of the inhibitor literature, including several frequently cited metabolic papers, used other compounds in the series or structurally unrelated inhibitors, and those results should not be attributed to 5-Amino-1MQ specifically.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →